Published in J Autoimmun on December 01, 2004
Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol (2005) 1.23
Accelerated atherosclerosis in patients with SLE--mechanisms and management. Nat Rev Rheumatol (2012) 1.08
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice. Lupus (2008) 0.92
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis (2007) 0.78
Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases. J Biol Chem (2014) 0.78
IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther (2015) 0.76
Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol (2012) 0.76
Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol (2014) 0.75
[T cell-dependent monocyte activation, TNFalpha and apolipoprotein A-I in autoimmunity and inflammation]. Z Rheumatol (2005) 0.75
Collective memory and spatial sorting in animal groups. J Theor Biol (2002) 8.85
Consensus decision making by fish. Curr Biol (2008) 2.85
Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med (2004) 2.33
Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol (2005) 2.23
The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol (2005) 2.13
Social networks in the guppy (Poecilia reticulata). Proc Biol Sci (2004) 1.95
Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood (2008) 1.91
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab (2002) 1.74
Hypothesis testing in animal social networks. Trends Ecol Evol (2011) 1.73
Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes (2003) 1.73
Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest (2011) 1.65
Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A (2004) 1.60
High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev (2002) 1.58
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Adipose tissue is a regulated source of interleukin-10. Cytokine (2005) 1.52
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thromb Haemost (2005) 1.47
Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res (2001) 1.47
Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol (2006) 1.46
Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet (2002) 1.44
Cell entry mechanism of enzymatic bacterial colicins: porin recruitment and the thermodynamics of receptor binding. Proc Natl Acad Sci U S A (2005) 1.44
A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost (2006) 1.42
[Carotid stents: role of evidence-based medicine!]. Rev Med Suisse (2010) 1.40
Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol (2010) 1.36
The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res (2002) 1.36
Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes (2005) 1.31
Association patterns and shoal fidelity in the three-spined stickleback. Proc Biol Sci (2002) 1.31
How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med (2013) 1.26
Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol (2005) 1.25
Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci (2002) 1.24
Competitive recruitment of the periplasmic translocation portal TolB by a natively disordered domain of colicin E9. Proc Natl Acad Sci U S A (2006) 1.24
Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab (2004) 1.23
Influence of antidepressants on hemostasis. Dialogues Clin Neurosci (2007) 1.23
Highly discriminating protein-protein interaction specificities in the context of a conserved binding energy hotspot. J Mol Biol (2004) 1.20
Microfluidic device generating stable concentration gradients for long term cell culture: application to Wnt3a regulation of β-catenin signaling. Lab Chip (2010) 1.20
Thermodynamic consequences of bipartite immunity protein binding to the ribosomal ribonuclease colicin E3. Biochemistry (2003) 1.20
Mutagenic scan of the H-N-H motif of colicin E9: implications for the mechanistic enzymology of colicins, homing enzymes and apoptotic endonucleases. Nucleic Acids Res (2002) 1.18
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol (2005) 1.17
Transcriptional profiling of colicin-induced cell death of Escherichia coli MG1655 identifies potential mechanisms by which bacteriocins promote bacterial diversity. J Bacteriol (2004) 1.17
Automated mapping of social networks in wild birds. Curr Biol (2012) 1.17
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
Allosteric beta-propeller signalling in TolB and its manipulation by translocating colicins. EMBO J (2009) 1.15
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
Opposite regulation of IL-1beta and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccharides or contact with T cells. J Immunol (2007) 1.14
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther (2007) 1.13
Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum (2002) 1.12
The cytotoxic domain of colicin E9 is a channel-forming endonuclease. Nat Struct Biol (2002) 1.10
Population-based study of SR-BI genetic variation and lipid profile. Atherosclerosis (2004) 1.09
Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum (2007) 1.08
Strength of social tie predicts cooperative investment in a human social network. PLoS One (2011) 1.08
Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum (2003) 1.08
Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther (2004) 1.07
Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine (2010) 1.06
Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant (2009) 1.06
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 1.05
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med (2004) 1.05
Social implications of the battle of the sexes: sexual harassment disrupts female sociality and social recognition. Proc Biol Sci (2009) 1.04
The lumicins: novel bacteriocins from Photorhabdus luminescens with similarity to the uropathogenic-specific protein (USP) from uropathogenic Escherichia coli. FEMS Microbiol Lett (2002) 1.04
Structural dynamics of the membrane translocation domain of colicin E9 and its interaction with TolB. J Mol Biol (2002) 1.04
Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J Leukoc Biol (2008) 1.03
Flexibility in the receptor-binding domain of the enzymatic colicin E9 is required for toxicity against Escherichia coli cells. J Bacteriol (2004) 1.01
Identification of the catalytic motif of the microbial ribosome inactivating cytotoxin colicin E3. Protein Sci (2004) 1.01
Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum (2008) 1.00
Minimizing perioperative blood loss and transfusions in children. Can J Anaesth (2006) 1.00
Energy-dependent immunity protein release during tol-dependent nuclease colicin translocation. J Biol Chem (2009) 0.99
Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis (2012) 0.99
The role of electrostatics in colicin nuclease domain translocation into bacterial cells. J Biol Chem (2007) 0.97
Profile of circulating cytokines: impact of OSA, obesity and acute cardiovascular events. Cytokine (2013) 0.97
Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost (2002) 0.97
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev (2007) 0.97
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2010) 0.97
Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med (2004) 0.96
Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine (2002) 0.96
Probing metal ion binding and conformational properties of the colicin E9 endonuclease by electrospray ionization time-of-flight mass spectrometry. Protein Sci (2002) 0.96
The temporal selfish herd: predation risk while aggregations form. Proc Biol Sci (2010) 0.95
The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol (2005) 0.95
Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides. Mol Immunol (2008) 0.95
NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost (2002) 0.94
The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood (2006) 0.93
Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med (2002) 0.93
Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa B/PU.1 binding site. Biochem J (2003) 0.93
Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS One (2009) 0.93
Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? Respir Med (2008) 0.93
Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci U S A (2010) 0.93